These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26405584)

  • 1. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
    Berinstein NL; Karkada M; Oza AM; Odunsi K; Villella JA; Nemunaitis JJ; Morse MA; Pejovic T; Bentley J; Buyse M; Nigam R; Weir GM; MacDonald LD; Quinton T; Rajagopalan R; Sharp K; Penwell A; Sammatur L; Burzykowski T; Stanford MM; Mansour M
    Oncoimmunology; 2015 Aug; 4(8):e1026529. PubMed ID: 26405584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic vaccines and cancer: focus on DPX-0907.
    Karkada M; Berinstein NL; Mansour M
    Biologics; 2014; 8():27-38. PubMed ID: 24596453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.
    Weir GM; Hrytsenko O; Stanford MM; Berinstein NL; Karkada M; Liwski RS; Mansour M
    Oncoimmunology; 2014; 3(8):e953407. PubMed ID: 25960932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4
    Onodi F; Maherzi-Mechalikh C; Mougel A; Ben Hamouda N; Taboas C; Gueugnon F; Tran T; Nozach H; Marcon E; Gey A; Terme M; Bouzidi A; Maillere B; Kerzerho J; Tartour E; Tanchot C
    Front Oncol; 2018; 8():517. PubMed ID: 30483475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration.
    Karkada M; Quinton T; Blackman R; Mansour M
    ISRN Oncol; 2013; 2013():753427. PubMed ID: 23533812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
    Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
    Front Immunol; 2018; 9():822. PubMed ID: 29755461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients.
    Wang XF; Kerzerho J; Adotevi O; Nuyttens H; Badoual C; Munier G; Oudard S; Tu S; Tartour E; Maillère B
    J Immunol; 2008 Jul; 181(1):431-9. PubMed ID: 18566409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
    Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
    Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.
    Srivastava R; Khan AA; Garg S; Syed SA; Furness JN; Vahed H; Pham T; Yu HT; Nesburn AB; BenMohamed L
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27847359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
    Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
    Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
    Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
    J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
    Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
    Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients.
    Gannon PO; Baumgaertner P; Huber A; Iancu EM; Cagnon L; Abed Maillard S; Maby-El Hajjami H; Speiser DE; Rufer N
    Clin Cancer Res; 2017 Jul; 23(13):3285-3296. PubMed ID: 27872103
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
    Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
    Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
    Front Immunol; 2018; 9():2968. PubMed ID: 30631324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.